-

CANO STOCK NEWS: Robbins LLP Investigates Cano Health, Inc. (CANO, CANO/WS) f/k/a Jaws Acquisition Corp. (JWS) on Behalf of Stockholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Cano Health, Inc. (NYSE: CANO) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws in relation to restating Cano's financials for year ended December 31, 2021. Cano provides primary care medical services to its members in the U.S. and Puerto Rico.

If you would like more information about our investigation of Cano Health, Inc.'s misconduct, click here.

What is this Case About: According to a complaint filed against Cano, on June 3, 2021, Jaws Acquisition Corp. consummated a merger with Primary Care (ITC) Intermediate Holdings, LLC, whereby Jaws changed its name to Cano Health, Inc. and began to provide primary care medical services.

On February 28, 2022, Cano announced "it will delay its fourth quarter and full year 2021 earnings release, conference call and 2022 guidance updates, previously scheduled for Monday, February 28, 2022." Cano advised that "in the course of finalizing its audit of the financial statements for the year ended December 31, 2021, the Company and its independent auditor … identified certain potential non-cash adjustments to account for revenue recognition under accounting standard ASC 606." Specifically, Cano advised that “[t]he adjustments relate to how and when the Company accrues revenue related to Medicare Risk Adjustments” and that “[t]he adjustments are expected to impact the timing of revenue recognition, by delaying recognition of certain amounts related to the Medicare Risk Adjustment to subsequent periods[.]” On this news, Cano's Class A common stock price fell over 6% on February 28, 2022.

When the Company filed its annual report for the quarter and year ended December 31, 2021, it "restated its financial statements for each of the quarterly periods ended March 31, 2021, June 30, 2021 and September 30, 2021 in the [2021 10-K.]” For example, the 2021 10-K reported that, as restated, capitated revenue decreased 2.13% for the three months ended March 31, 2021; 13.11% for the three months ended June 30, 2021; and 5.58% for the three months ended September 30, 2021.

Next Steps: If you acquired shares of Cano Health, Inc. (CANO) between May 18, 2020 and February 25, 2022, you have legal options. Contact us for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Cano Health, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:CANO

Release Summary
CANO STOCK NEWS: Robbins LLP Investigates Cano Health, Inc. (CANO, CANO/WS) f/k/a Jaws Acquisition Corp. (JWS) on Behalf of Stockholders
Release Versions

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800)...

Investor Notice: Robbins LLP Informs Investors of the Gemini Space Station, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gemini Space Station, Inc. (NASDAQ: GEMI) Class A common stock pursuant and/or traceable to the Company's September 12, 2025 initial public offering ("IPO"), and/or Gemini Space Station, Inc. securities between September 12, 2025 and February 17, 2026. Gemini was founded to develop and operate a cryptocurrency platform. For more information, s...

uniQure N.V. Stockholders Should Contact Robbins LLP for Information About Leading the QURE Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? September 24, 2025 – October 31, 2025 W...
Back to Newsroom